Tightening share structure ahead of fully-funded, maiden drill program in Red Lake WHITE ROCK, BC / ACCESS Newswire / March 27, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") announces that its Board of Directors has approved a consolidation of the Company's issued and outstanding common shares on the basis of every nine point nine (9.9) pre-consolidation common shares for every one (1) post-consolidation common share (the "Consolidation"). Pursuant to the Business Corpor ...

Athena Gold Provides Exploration Update From Excelsior Springs, Nevada ELEMENT--Back to the NewsroomAthena Gold Provides Exploration Update From Excelsior Springs, NevadaDrilling returns 1.25 g/t Au over 33.54m; Buster Trend further expandedWHITE ROCK, BC / ACCESS Newswire/ March 19, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada. Mammoth Minerals Limited (ASX: M79) (formerly Firetail ...

Core Viewpoint - Athena Gold Corporation has successfully completed the acquisition of the Forester Gold Project, enhancing its position as a disciplined explorer in high-potential areas near major gold producers [1] Acquisition Details - The acquisition involved purchasing Last Bounty Gold Corp., which holds a 100% interest in the Forester Gold Project, through a share purchase agreement dated February 25, 2026 [1] - Athena issued 42,000,000 common shares at a deemed price of CAD $0.08 per share, representing approximately 12% of the Company on a non-diluted basis [1] - The transaction was conducted at arm's length, with no finder's fees paid and no new insiders created upon closing [1] Project Potential - The Forester Gold Project is strategically located near Orla Mining's Musselwhite Mine, with favorable geology indicating strong potential for near-surface, bulk-tonnage, orogenic gold systems [1] - Historical drill intercepts at Forester show potential for both high-grade, narrow-vein and low-grade, bulk-tonnage gold mineralization [1] - The Laird Lake project, another key asset of the Company, is situated along trend from West Red Lake's Madsen Mine, with drill permits in hand and plans to mobilize rigs for exploration [1] Company Overview - Athena Gold Corporation focuses on mineral exploration and the acquisition of mineral property assets, aiming to develop economic precious and base metal properties across North America [1] - The Laird Lake project covers over 7,000 hectares along more than 10 km of the Balmer-Confederation Assemblage contact, with recent surface sampling results showing up to 373 g/t Au [1] - The Excelsior Springs Project in Nevada is also under an earn-in option with Mammoth Minerals Limited, covering over 2,500 hectares and including at least three historic mines [1]

Core Viewpoint - Athena Gold Corporation is advancing its exploration efforts at the Excelsior Springs Project in Nevada and the Laird Lake Project in Ontario, with significant developments in both projects [1]. Group 1: Excelsior Springs Project - Mammoth Minerals Limited is actively exploring the Excelsior Springs Project under an option agreement to acquire an 80% interest over five years [1]. - This agreement allows Athena Gold Corporation to benefit from a free-carry to a Definitive Feasibility Study after Mammoth Minerals earns its interest [1]. Group 2: Laird Lake Project - Permits are currently pending for the Laird Lake Project, indicating ongoing regulatory processes that may impact future exploration activities [1].

Core Viewpoint - ATHA Energy Corp. has successfully closed approximately C$63 million in new financing to support the exploration and development of its Angilak Project in Nunavut [1] Financing Details - The financing includes a private placement of USD$25 million (approximately C$34,130,000) in unsecured convertible debentures with Queen's Road Capital Investment Ltd. [1] - Additionally, the company completed a brokered private placement of charity "flow-through" common shares, issuing 28,186,500 FT Shares at a price of C$1.02, resulting in aggregate gross proceeds of C$28,750,230 [1]

Core Viewpoint - ATHA Energy Corp. has announced an increase in the size of its private placement with Queen's Road Capital Investment Ltd. due to strong investor demand [1] Group 1 - The private placement was initially announced on January 13th, 2026 [1] - The offering is being conducted in response to significant interest from investors [1]

Company Overview - Athena Gold Corporation is engaged in mineral exploration and acquisition of mineral property assets, focusing on developing economic precious and base metal properties across North America [2] - The company holds significant projects including the Laird Lake project in Ontario, covering over 7,000 hectares with recent surface sampling results showing up to 373 g/t Au [2] - Athena Gold also has the Excelsior Springs Project in Nevada, spanning over 2,500 hectares and covering at least three historic mines, currently under an earn-in option with Mammoth Minerals Limited [2] Industry Event - The Vancouver Resource Investment Conference (VRIC) is a key event in the junior mining investment sector in Canada, attracting over 5,000 mining investors annually [1] - The 2026 conference will feature over 120 expert speakers and a marketplace of over 300 investment opportunities in the mining industry, ranging from early-stage exploration to advanced producing mines [1]

Core Viewpoint - ATHA Energy Corp. has announced a binding term sheet with Queen's Road Capital Investment Ltd. for a private placement of USD$20 million in unsecured convertible debentures [1] Group 1: Company Overview - ATHA Energy Corp. is engaging in a private placement to raise capital through the issuance of unsecured convertible debentures [1] - The principal amount of the offering is USD$20 million, which is approximately CAD$27.7 million [1] Group 2: Financial Details - The offering consists of unsecured convertible debentures, indicating a potential for conversion into equity at a later date [1] - The transaction is expected to enhance the company's financial position and support its growth initiatives [1]

Core Viewpoint - Athira Pharma, Inc. has rebranded as LeonaBio, Inc. to reflect its strategic focus on developing lasofoxifene for metastatic breast cancer treatment, currently in Phase 3 trials [1][2] Company Overview - LeonaBio is a clinical-stage biopharmaceutical company focused on innovative therapeutics for diseases with high unmet medical needs, including metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [10] - The company aims to advance a pipeline of late-stage assets to maximize clinical and commercial impact [2] Name and Ticker Change - The name change to LeonaBio symbolizes strength and resilience, aligning with the company's mission to support patients facing serious diseases [2] - The new ticker symbol "LONA" will be effective on January 12, 2026, on The Nasdaq Capital Market [1] Lead Drug Candidates - Lasofoxifene and ATH-1105 are the lead drug candidates, targeting treatment-resistant metastatic breast cancer and ALS, respectively [3][10] - Lasofoxifene is in a Phase 3 trial (ELAINE-3) with over 50% enrollment, and data is expected in mid-2027 [3][6] Licensing and Financing - LeonaBio secured an exclusive global license for lasofoxifene from Sermonix Pharmaceuticals, excluding Asia and certain Middle Eastern countries [4] - The company raised $90 million through a private placement, with potential additional funding of up to $146 million from warrants, to support lasofoxifene's development [4] Drug Candidate Details - Lasofoxifene is a selective estrogen receptor modulator (SERM) designed to target both wild-type and mutant estrogen receptors, addressing a critical unmet need in metastatic breast cancer [5] - ATH-1105 is a next-generation small molecule aimed at treating neurodegenerative diseases, currently in Phase 1 trials with plans for a Phase 2 trial in ALS patients in early 2026 [7][8]

Core Viewpoint - Athira Pharma, Inc. has rebranded as LeonaBio, Inc. following the acquisition of rights to develop and commercialize lasofoxifene for metastatic breast cancer, reflecting the company's commitment to innovation and leadership in addressing unmet medical needs [1][2] Group 1: Company Name Change and Strategy - The name change to LeonaBio symbolizes strength and resilience, aligning with the company's mission to deliver transformative therapies for serious diseases [2] - The new ticker symbol "LONA" will be used on The Nasdaq Capital Market starting January 12, 2026, without affecting the company's legal structure or operations [1][2] Group 2: Drug Development Focus - LeonaBio's lead drug candidates include lasofoxifene and ATH-1105, targeting treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [3][9] - Lasofoxifene is currently in a Phase 3 clinical trial (ELAINE-3), with over 50% enrollment and data expected in mid-2027 [3][6] Group 3: Licensing and Financing - The company secured an exclusive global license for lasofoxifene from Sermonix Pharmaceuticals, with an upfront financing of $90 million and potential additional funding of up to $146 million through warrants [4] - This financing is expected to support lasofoxifene's development through key clinical and regulatory milestones, with sufficient capital for operations into 2028 [4] Group 4: Drug Candidate Details - Lasofoxifene is a selective estrogen receptor modulator (SERM) designed to target both wild-type and mutant estrogen receptors, addressing critical unmet needs in metastatic breast cancer [5] - ATH-1105 is a next-generation small molecule drug candidate aimed at treating neurodegenerative diseases, currently in clinical development for ALS [7][8]